The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
July 22nd 2024
Here's some of what is coming soon to NeurologyLive® this week.
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, ...
September 16, 2024
Register Now!
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Disparities in Memory Clinic Visits and Dementia Severity Identified in Disadvantaged Neighborhoods
September 28th 2023Patients who self-identified as Black and were living in less affluent neighborhoods were less likely to be seen in one large memory clinic as well as have more severe dementia at initial visit.
Perfecting a Cocktail of Approaches to Treat Alzheimer Disease: Richard Isaacson, MD
September 27th 2023The director of the Center for Brain Health and Alzheimer Prevention Clinic at Florida Atlantic University provided perspectives on the multimodal, multitargeted approach needed to treat Alzheimer disease. [WATCH TIME: 5 minutes]
Role of Gut Microbiome, Alpha Synuclein in the Prodromal Stage of Parkinson Disease
September 25th 2023Virginia Gao, MD, PhD, a movement disorders fellow at Weill Cornell Medicine, discussed several topics related to the use of biomarkers in the prodromal stages of neurodegenerative disorders like Parkinson disease.
BXCL501 Meets Primary Efficacy End Point in Phase 3 TRANQUILITY II Trial of Alzheimer Agitation
September 23rd 2023Among 443 episodes in 149 patients treated with different doses of BXCL501 over 12 weeks, the 60 mcg dose showed a reduction in agitation for the first and all treated episodes at 1 and 2 hours.
Targeting Cognitive Impairment of Long COVID With Brain Stimulation
September 21st 2023Leigh Charvet, PhD, professor of neurology at the NYU Grossman School of Medicine, talked about a trial that aims to address cognitive impairment in patients with long COVID through a unique, remote, and home-based treatment approach.
Limited Eligibility Among Older Adults for New Alzheimer Monoclonal Antibody Therapies
September 21st 2023A study examining eligibility criteria for Alzheimer agent trials showed that a significant proportion of older adults with early cognitive impairment may not qualify for these therapies because of health conditions and other factors.
NeuroVoices: Ruth Schneider, MD, on Addressing Psychosis in Lewy Body Diseases
September 20th 2023The associate professor in the department of neurology at the University of Rochester provided insight on her presentation on psychosis in Parkinson disease and related disorders given at the 2023 ANA Annual Meeting.
Alzheimer Agent ALZ-801 Improves Cognition, Reduces Relevant Biomarker Levels in 2-Year Analysis
September 13th 2023Over a 2-year treatment period, patients on ALZ-801 demonstrated significant correlations between effects on volumetric MRI outcomes and 3 cognitive scales, suggesting cognitive gains are a result of preservation of brain structures from neurodegeneration and atrophy.
Performance of Simulated Real-Life Daily Functioning Test Associated With Risk of Alzheimer Disease
September 13th 2023Findings from a recent exploratory study suggest that assessing daily functioning in a more sensitive way may identify Alzheimer disease before a patient develops more pronounced cognitive changes.
Collaborative Efforts for Health Equity in Alzheimer Disease Genetic Research: Adam Naj, PhD
September 12th 2023The genetic epidemiologist at the University of Pennsylvania discussed a recent study that highlighted the importance of diverse samples in genetic research for Alzheimer disease in helping to uncover hidden genetic risk factors. [WATCH TIME: 2 minutes]
Treatment Effect of Neflamapimod Enriched When Excluding High P-Tau181 Level Patients
September 11th 2023The combined preclinical and clinical data with neflamapimod suggest the therapy has potential to be the first disease-modifying treatment for dementia with Lewy Bodies, demonstrating a positive impact on cognition, function, and mobility.